Hua Medicine (Shanghai) Ltd. (2552.HK)

1.580 +0.080 (+5.33%) At close: 04:08PM HKT

Hua Medicine (Shanghai) Ltd.

Building 2, Lane 36
Xuelin Road Pudong New Area
Shanghai 201203
China
86 21 3810 1800
https://www.huamedicine.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 177

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Li Chen Ph.D.	Founder, CEO & Executive Director	8.67M	N/A	1963
Mr. Chien Cheng Lin J.D.	Executive VP, Chief Strategy Officer & Executive Director	6.61M	N/A	1971
Dr. Fuxing Tang Ph.D.	CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA	N/A	N/A	1967
Dr. Changhong Li Ph.D.	Chief Scientific Officer	N/A	N/A	1969
Mr. Chengde Wang	Head of IR	N/A	N/A	1948
Dr. Yi Zhang M.D., Ph.D.	Senior VP of Pharma Development, Chief Medical Officer – China and Executive Director	N/A	N/A	1975
Mr. Ying Xie M.B.A.	VP of Quality Assurance Division & Chief Quality Officer	N/A	N/A	N/A
Ms. Wing Yan Yuen FCIS, FCS	Company Secretary	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. The company was incorporated in 2011 and is based in Shanghai, China.

Corporate governance

Hua Medicine (Shanghai) Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.